Guan, J. et al. 2021. Prognostic value of low skeletal muscle mass in hepatocellular carcinoma patients treated with sorafenib or lenvatinib: A meta-analysis. EXCLI Journal. 20, (Jan. 2021), 1–16. DOI:https://doi.org/10.17179/excli2020-3111.